Glioblastoma-derived Tumor Cells Induce Vasculogenic Mimicry through Flk-1 Protein Activation

被引:116
作者
Francescone, Ralph [1 ]
Scully, Steve [1 ]
Bentley, Brooke [2 ]
Yan, Wei [2 ]
Taylor, Sherry L. [3 ]
Oh, Dennis [3 ]
Moral, Luis [4 ]
Shao, Rong [1 ,2 ,5 ]
机构
[1] Univ Massachusetts, Mol & Cellular Biol Program, Morrill Sci Ctr, Amherst, MA 01003 USA
[2] Pioneer Valley Life Sci Inst, Springfield, MA 01199 USA
[3] Tufts Univ, Dept Neurosurg, Baystate Med Ctr, Springfield, MA 01199 USA
[4] Tufts Univ, Dept Pathol, Baystate Med Ctr, Springfield, MA 01199 USA
[5] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA
基金
美国国家卫生研究院;
关键词
BEVACIZUMAB PLUS IRINOTECAN; VASCULAR CHANNEL FORMATION; RECEPTOR TYROSINE KINASE; STEM-LIKE CELLS; THERAPEUTIC IMPLICATIONS; RECURRENT GLIOBLASTOMA; ENDOTHELIAL-CELLS; MALIGNANT GLIOMAS; BREAST-CANCER; LUNG-CANCER;
D O I
10.1074/jbc.M111.334540
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glioblastoma (GBM) is extremely aggressive and essentially incurable. Its malignancy is characterized by vigorous microvascular proliferations. Recent evidence has shown that tumor cells display the ability to drive blood-perfused vasculogenic mimicry (VM), an alternative microvascular circulation independent of endothelial cell angiogenesis. However, molecular mechanisms underlying this vascular pathogenesis are poorly understood. Here, we found that vascular channels of VM in GBM were composed of mural-like tumor cells that strongly express VEGF receptor 2 (Flk-1). To explore a potential role of Flk-1 in the vasculogenesis, we investigated two glioblastoma cell lines U87 and GSDC, both of which express Flk-1 and exhibit a vascular phenotype on Matrigel. Treatment of both cell lines with either Flk-1 gene knockdown or Flk-1 kinase inhibitor SU1498 abrogated Flk-1 activity and impaired vascular function. Furthermore, inhibition of Flk-1 activity suppressed intracellular signaling cascades, including focal adhesion kinase and mitogen-activated protein kinase ERK1/2. In contrast, blockade of VEGF activity by the neutralizing antibody Bevacizumab failed to recapitulate the impact of SU1498, suggesting that Flk-1-mediated VM is independent of VEGF. Xenotransplantation of SCID/Beige mice with U87 cells and GSDCs gave rise to tumors harboring robust mural cell-associated vascular channels. Flk-1 shRNA restrained VM in tumors and subsequently inhibited tumor development. Collectively, all the data demonstrate a central role of Flk-1 in the formation of VM in GBM. This study has shed light on molecular mechanisms mediating tumor aggressiveness and also provided a therapeutic target for patient treatment.
引用
收藏
页码:24821 / 24831
页数:11
相关论文
共 61 条
[1]   A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells [J].
Basu, Gargi D. ;
Liang, Winnie S. ;
Stephan, Dietrich A. ;
Wegener, Lee T. ;
Conley, Christopher R. ;
Pockaj, Barbara A. ;
Mukherjee, Pinku .
BREAST CANCER RESEARCH, 2006, 8 (06)
[2]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[3]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[4]   Platelet-derived growth factor receptor β and vascular endothelial growth factor receptor 2 bind to the β3 integrin through its extracellular domain [J].
Borges, E ;
Jan, YW ;
Ruoslahti, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (51) :39867-39873
[5]   Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood [J].
Chang, YS ;
di Tomaso, E ;
McDonald, DM ;
Jones, R ;
Jain, RK ;
Munn, LL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (26) :14608-14613
[6]   Vasculogenic mimicry-potential target for glioblastoma therapy: an in vitro and in vivo study [J].
Chen, Yinsheng ;
Jing, Zhitao ;
Luo, Cheng ;
Zhuang, Minghua ;
Xia, Junzhe ;
Chen, Zhongping ;
Wang, Yunjie .
MEDICAL ONCOLOGY, 2012, 29 (01) :324-331
[7]   Mosaic tumor vessels: Cellular basis and ultrastructure of focal regions lacking endothelial cell markers [J].
di Tomaso, E ;
Capen, D ;
Haskell, A ;
Hart, J ;
Logie, JJ ;
Jain, RK ;
McDonald, DM ;
Jones, R ;
Munn, LL .
CANCER RESEARCH, 2005, 65 (13) :5740-5749
[8]   Alternative vascularization mechanisms in cancer -: Pathology and therapeutic implications [J].
Dome, Balazs ;
Hendrix, Mary J. C. ;
Paku, Sandor ;
Tovari, Jozsef ;
Timar, Jozsef .
AMERICAN JOURNAL OF PATHOLOGY, 2007, 170 (01) :1-15
[9]   Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis [J].
Ebos, John M. L. ;
Lee, Christina R. ;
Cruz-Munoz, William ;
Bjarnason, Georg A. ;
Christensen, James G. ;
Kerbel, Robert S. .
CANCER CELL, 2009, 15 (03) :232-239
[10]   Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2 [J].
Eichmann, A ;
Corbel, C ;
Nataf, V ;
Vaigot, P ;
Breant, C ;
LeDouarin, NM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (10) :5141-5146